Cumberland Pharmaceuticals
Mr. Krogulski joined Cumberland’s Board of Directors in 2017. He has over 40 years of experience in security analysis and portfolio management and is currently the Managing Partner and Chief Investment Officer of Berkshire Asset Management, LLC. Berkshire is an independent SEC registered Pennsylvania based investment advisory firm with over $3.5 billion in assets under supervision as of December 31, 2022. In addition, Mr. Krogulski is currently on the board of Allied Services Integrated Health System. He previously served as a Director of Landmark Community Bank (LDKB: NASDAQ) and numerous nonprofit organizations. Mr. Krogulski holds a B.S. in finance from Indiana University of Pennsylvania and earned his M.B.A. from Wilkes University. In addition, he holds the Chartered Financial Analyst designation.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Cumberland Pharmaceuticals
2 followers
Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. With a focus on underserved niche markets, including hospital acute care and gastroenterology, they deliver products that serve patients in the U.S. market. Cumberland also makes its products available to patients internationally through select strategic partnerships. They own the worldwide rights to all their brands. While Cumberland’s commercial capabilities are focused on the U.S. market, their business development team is actively pursuing opportunities to make their brands available to patients in markets around the globe. Their primary mission is to improve upon patient care with products that offer clear advantages over existing treatments. They also strive to deliver solutions that may help reduce costs for healthcare providers and, ultimately, patients.